Welcome to the Wet AMD & DME Drug Development Summit

The Wet AMD & DME Drug Development Summit comes at a critical juncture, as the research community progresses novel drug candidates targeting angiogenesis-driven disease and a pandemic further exposes the current treatment limitations for a global aging population.

The treatment landscape for Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME) has dramatically changed since the first Anti-VEGF therapies were approved for ocular neovascularization. However, the industry continues to explore new therapeutic avenues to improve treatment convenience, efficacy and/or reduce the frequency of invasive procedures. As a dedicated industry forum, the Wet AMD & DME Drug Development Summit aims to address the specific challenges for the biopharmaceutical and biotechnology industry in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care is this vast ophthalmology indication.

Expert Speakers Include:

Feedback from the Dry AMD Therapeutic Development Summit:

“Thorough update on the scientific, regulatory and commercial status of dry AMD”

CEO, Drusolv Therapeutics

“Informative and enlightening”

Chief Medical Officer, Eyevensys